|
|
 |
|
 |
Tri-Luma® Cream is significantly more effective than all other combinations of these active ingredients¹
Percentage of patients with complete clearing at 8 weeks¹*
| Therapy |
% |
P |
| RA + HQ + FA |
28.6% |
<.001 |
| RA + HQ |
10.1% |
<.001 |
| RA + FA |
1.9% |
<.001 |
| HQ + FA |
3.1% |
<.001 |
|
*Two 8-week, multicenter, randomized, investigator-blind studies. Percentage of patients who experienced complete clearing on or before day 56; intent-to-treat population comparing a hydrophilic cream formulation containing tretinoin 0.05%, hydroquinone 4.0%, and fluocinolone acetenoide 0.01% (RA+HQ+FA) with the dual-combination agents tretinoin plus hydroquinone (RA+HQ), tretinoin plus fluocinolone acetonide (RA+FA), and hydroquinone plus fluocinolone acetonide (HQ+FA). Asterisk indicates P<.001 vs. dual-therapy combinations.
Percentage of patients with complete/near-complete clearing at 8 weeks¹*
| Therapy |
% |
P |
| RA + HQ + FA |
77% |
<.001 |
| RA + HQ |
46.8% |
<.001 |
| RA + FA |
27.3% |
<.001 |
| HQ + FA |
42.2% |
<.001 |
|
*Two 8-week, multicenter, randomized, investigator-blind studies. Percentage of patients who experienced complete or near-complete clearing at day 56; intent-to-treat population comparing a hydrophilic cream formulation containing tretinoin 0.05%, hydroquinone 4.0%, and fluocinolone acetenoide 0.01% (RA+HQ+FA) with the dual-combination agents tretinoin plus hydroquinone (RA+HQ), tretinoin plus fluocinolone acetonide (RA+FA), and hydroquinone plus fluocinolone acetonide (HQ+FA). Asterisk indicates P<.001 vs. dual-therapy combinations.
In 77% of patients, melasma was cleared or mild after 8 weeks of treatment.¹
*Individual results may vary. In studies, 29% of patients achieved complete clearing.
Proven in the Largest, Most Diverse Study of Melasma2
- Open-label community-based trial
- 393 centers
- 1290 patients with moderate-to-severe melasma
- Caucasian (800); Hispanic (204); African American/Black (130); Asian (94); American Indian, Alaskan Native, Pacific Islander (14); Other (43); Not Reported (5)
- Efficacy and safety were measured
Study shows quality of life2 improves after using Tri-Luma® Cream.
- A subset of 1076 patients were asked to participate in the quality-of-life assessment
- For more information, read about The Psychosocial Impact of Melasma
Reference: 1. Taylor SC, et al. Efficacy and Safety of a New Triple-Combination Agent for the Treatment of Facial Melasma. Cutis. 2003; 72: 67-72.
2. Balkrishnan, R., et al. Improved Quality of Life with Effective Therapy of Facial-Melasma. Journal of Drugs in Dermatology. 2004: 3(3): 247-251.
3. Tri-Luma® Cream package insert.
Please see full prescribing information.
|
|
|
